Seminal
The magazine and atlas of EU-funded researchA new publication from the web and AI team at Scott Charnley

Atlas / Germany

European Innovation Council · Running

GrownValve A prosthetic heart valve for adults and children, made from the patient’s own tissue, a replacement heart valve that lasts a lifetime

Coordinator
Grownvalve GmbH, Germany
Runs
1 April 2022 to 31 July 2025
Status
Running
EU funding
€2.5m
Total cost
€3.6m
Partners
1 organisations in 1 countries
Type
European Innovation Council
Grant agreement
190188598

What the project is doing

In the project's own words, from its summary on CORDIS.

Each year 400,000 people are born with heart valve defects worldwide. Moreover, in the western world, 1 in 8 healthy adults will develop a heart valve problem during their lifetime. Current artificial heart valves made from animal or human donor tissue carry a high risk of tissue rejection, degradation and calcification that limit their lifespan to about 10 years, forcing patients to undergo risky cardiac re-surgery. For children, no dedicated valve product exists, thus, paediatric patients can endure 4-5 surgeries between 0-18 years of age as their bodies outgrow each replacement heart valve.

At GrOwnValve we have developed a paradigm shift in heart valve technology: the first autologous valve, grown from the patient’s own tissue, crafted using medical imaging and a 3D printing technique. Our valve lasts a lifetime, eliminating tissue rejection and surgical risks associated with repeated surgery (bleeding, infection and death).

Topics

Who is involved

OrganisationCityCountryRole
Grownvalve GmbHBerlinGermanyCoordinator

Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI